Tetra BioPharma (OTCQB:TBPMF; CSE:TBP) appointed Bernard Fortier to the position of CEO, effective July 24.
Andre Rancourt, previous interim CEO, will take the position of chairman. Andre Audet will step down as chairman of the board of directors but will continue to serve as a board member.
Mr. Fortier has over 20 years of international experience in management and business development in the biopharma, specialized medical nutrition and medical fields., including key commercial roles at Serono Canada (now EMD Serono) in the multiple sclerosis field, including national sales manager for the neurology business unit.
In 2010, Mr. Fortier became the country manager for Nutricia Canada, the specialized medical nutrition division of Groupe Danone. He was recruited in 2012 to launch a new pharmaceutical company, Orimed Pharma.
In a statement, Mr. Rancourt said Mr. Fortier has a clear mandate from the board, to grow revenue and build Tetra as a global leader in pharmaceutical cannabis. “Going forward, we will be placing considerable efforts in expanding Tetra in the U.S. market,” he added.